Astrana Health Credits AI-Native Platform as Q2 Revenue Climbs 49%

Astrana Health reported stronger second-quarter results on August 6 and raised its full-year adjusted EBITDA guidance after executives credited the company's AI-native healthcare platform and physician-centric operating model for continued growth.

The company reported revenue of $972.5 million for the quarter ended June 30, up 49% from a year earlier. Net income attributable to Astrana Health more than doubled to $19.7 million, while adjusted EBITDA increased 43% to $68.9 million. Adjusted diluted earnings per share rose 45% to $0.80. The company reaffirmed its 2026 revenue outlook of $3.8 billion to $4.1 billion and increased adjusted EBITDA guidance to $255 million to $280 million from $250 million to $270 million.

"Our second quarter results reflect the strength of our AI-native platform, the resilience of our physician-centric model, and the disciplined execution of our teams," Brandon Sim, President and Chief Executive Officer of Astrana Health, said in the earnings release.

AI Strategy Expands Across Physician Network

Astrana also announced the appointments of Daniel Rothman as President of Physician Enterprise and Vishal Gupta as Senior Vice President of Enterprise Transformation as it expands its technology platform and physician network. The company said its accountable care organizations generated $120.4 million in gross shared savings for the 2024 performance year while continuing to expand Medicare Advantage partnerships in Hawaii and Texas. 

Investor materials released alongside the earnings report showed full-risk arrangements accounted for 81% of capitated revenue in the second quarter, up from 35% in 2021, reflecting the company's continued shift toward value-based care models.

Platform Scale Supports Growth

Astrana's investor materials show the company supports more than 20,000 providers serving approximately 1.55 million patients through affiliated physician groups, clinics and management services organizations. The company's AI strategy mirrors a shift toward embedding AI into core healthcare platforms. while healthcare systems increasingly measure AI by improvements in clinician productivity and patient capacity. 

Although quarterly revenue came in slightly below some analyst expectations, stronger profitability and the higher adjusted EBITDA outlook drew investor attention following the earnings release. Management maintained its revenue guidance and said its physician-centric operating model and AI-native platform position the company for continued growth through the remainder of 2026.